拉丁美洲未来十年的生物类似药:一个机会的窗口
1Universidad Catolica del Norte (Chile), Escuela de Ciencias Empresariales, Coquimbo, Chile.
拉丁美洲生物仿制药市场准备快速增长,为生物制药提供负担得起的替代品. 关键的驱动因素包括慢性疾病,专利到期和人工智能,尽管监管协调仍然是一个挑战.
科学领域:
- 药物经济学 药物经济学
- 卫生政策 卫生政策
- 生物技术是生物技术.
背景情况:
- 生物类似药在拉丁美洲为生物药物提供了经济高效的替代品.
- 市场增长是由负担得起的医疗保健,慢性疾病,专利到期和人工智能的需求驱动的.
- 阿根廷,巴西和墨西哥是拥有成熟监管框架的关键市场.
研究的目的:
- 分析未来十年在巴西,墨西哥和阿根廷的生物类似药市场机会.
- 评估监管框架,机构质量和慢性病患者的负担能力.
- 检查人工智能 (AI) 在生物类似研究和开发 (R&D) 中的作用.
主要方法:
- 审查阿根廷,巴西和墨西哥的监管格局.
- 分析市场趋势和影响生物类似药的经济因素.
- 评估影响生物类似接入的机构质量和公共政策.
主要成果:
- 拉丁美洲生物类似药的显著增长潜力.
- 在研究国家确定已批准的生物类药物.
- 在监管协调和制度质量方面存在挑战.
结论:
- 改善监管框架和制度质量对于生物类似药市场的扩张至关重要.
- 投资研发能力,包括人工智能,对于未来的增长至关重要.
- 需要进行战略规划,以最大限度地提高生物类似药对患者的益处.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
相关概念视频
Bioequivalence: Overview
Biopharmaceutics and Pharmacokinetics: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Microorganisms in Medicine and Therapeutics
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
